May 12, 2025 — Mangoceuticals Inc. (NASDAQ: MGRX) is vaulting into one of consumer wellness’s fastest-growing delivery formats—the oral pouch—by acquiring Canadian innovator Smokeless Technology Corp. and appointing former Philip Morris and JUUL Labs executive Tim Corkum to build a dedicated Pouch Division. “Mangoceuticals has given me the reins to run with this phenomenal opportunity,” Corkum told InvestorNews host Tracy Hughes, emphasizing the synergy with the company’s telemedicine brands MangoRx and PeachesRx, which already serve the erectile-dysfunction, hormone-replacement, hair-growth and weight-management markets. The April 25 acquisition furnishes Mangoceuticals with intellectual property, product formulations and distribution relationships precisely as the U.S. nicotine-pouch segment tops US$3.1 billion in annual sales and analysts project the global oral-pouch market to exceed US$37 billion by 2032.
Corkum underscored the scale of the opportunity, noting that the addressable market extends far beyond nicotine alternatives. “If you look at some of the categories that Mangoceuticals already participates in, we’re talking about half a trillion dollars,” he said, citing nutraceutical pouches that could deliver energy, mood, focus, weight-loss and erectile-dysfunction ingredients. With 22 years at Philip Morris and recent leadership of JUUL Labs Canada behind him, Corkum intends to apply a consumer-packaged-goods playbook: “The runway is huge and I’m excited to leverage my experience to get it there,” he explained, adding that competitive secrecy around forthcoming SKUs is deliberate.
Detailing the science, Corkum contrasted pouches with oral strips: users “tuck the pouch up between your gum and your cheek,” allowing compounds to be absorbed buccally rather than degraded through the stomach and liver—a pathway that “loses some of their potency and is hard on the liver.” Looking ahead, he said shareholders should watch for “key partnerships—manufacturing…product development…distribution—anything that can help you produce and scale at the level that’s necessary.” As both executive and investor, Corkum framed those milestones as the next proofs of progress for Mangoceuticals’ push to become “a high-torque nutraceutical platform with multi-format delivery potential.”
To access the complete InvestorNews interview, click here
Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here
About Mangoceuticals, Inc.
Mangoceuticals, Inc. is focused on developing a variety of men’s and women’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management for men under the brands “MangoRx” and weight management products for women under the brand “PeachesRx”. Interested consumers can visit MangoRx’s or PeachesRx’s telemedicine platform for more information. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s and/or PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep.
To learn more about Mangoceuticals, Inc., click here
Disclaimer: Mangoceuticals, Inc. is an advertorial member of InvestorNews Inc.
This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.
Leave a Reply